Tag: result

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A ordinary shares of Sportradar Group AG (NASDAQ: SRAD) between November 7, 2024 and April 21, 2026, inclusive (the “Class Period”), of the important July 17, 2026 lead plaintiff deadline.

Los Angeles, CA, June 09, 2026 (GLOBE NEWSWIRE) -- Aperture AC (the “Company”) (Nasdaq: APURU) announced today that on June 10, 2026, the Company’s units will no longer trade, and that the Company’s Class A ordinary shares and rights, which together comprise the units, will commence trading separately. The Class A ordinary shares and rights will be listed on the Nasdaq Capital Market and trade with the ticker symbols “APUR” and “APURR”, respectively. This is a mandatory and automatic separation, and no action is required by the holders of units.

Dallas, TX, June 09, 2026 (GLOBE NEWSWIRE) -- Vivakor, Inc. (Nasdaq: VIVK) (“Vivakor” or the “Company”), an integrated provider of energy transportation, storage, reuse, and remediation services, today announced financial and operational results for the three months ended March 31, 2026.

Royal Uranium Approval Expected to Advance Company's Potential Transformation into a Diversified Energy Platform

Agreement expected to supply 40,000 tons per year of plastic waste feedstock, representing approximately 50% of the expected requirement for Abundia’s first Cedar Port plant

VenHub enters the Florida market through a new operator-led deployment model, marking a key step in its U.S. commercial rollout

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham 

- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma

- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers